NCE-1 Intelligence & Market Opportunity

Izervay

Avacincaptad Pegol

Ophthalmic

Intravitreal Solution

Izervay is a monthly injection into the eye to treat geographic atrophy caused by age-related macular degeneration. It slows vision loss by targeting a key protein involved in retinal cell death.

Approval Date

04-Aug-23

NCE-1 Date

04-Aug-27

NCE Date

04-Aug-28

Commercial snapshot

Market performance & projections

Revenue ($M)

499

CAGR (%)

0.2555

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

766

2027

932

2028

1089

2029

1240

2030

1368

2031

1498

2032

1626

Molecule profile

Details & specifications

Molecule

Avacincaptad Pegol

Innovator

IVERIC BIO INC

Dosage Form

Intravitreal Solution

Strength

EQ 2 mg base/0.1 mL

Therapeutic Category

Ophthalmic

Usage

To treat geographic atrophy secondary to age-related macular degeneration

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.